Abstracts Archive - Page 1539 of 2425 - ACR Meeting Abstracts

Abstract Number: 1824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients
Samantha Slight-Webb¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴, Joel M. Guthridge⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: The management of systemic lupus erythematosus (SLE) is complicated by a heterogeneous clinical presentation. Currently, mycophenolate mofetil (MMF) is a commonly used medication to…
Abstract Number: 1825 • 2016 ACR/ARHP Annual Meeting
the Non-Coding Genome and the Genetics of Systemic Lupus
Joyce Hui-Yuen¹, Lisha Zhu², Lai Ping Wong³, Kaiyu Jiang⁴, Yanmin Chen⁴, Tao Liu⁵ and James Jarvis⁶, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Biochemistry, University at Buffalo, Buffalo, NY, ³Pediatrics, University at Buffalo, Buffalo, NY, ⁴Pediatrics, The University at Buffalo, Buffalo, NY, ⁵Department of Biochemistry, University at Buffalo, Buffalo, NY, ⁶Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system, complex disease believed to be triggered by gene-environment interactions. While we have made considerable progress in investigation…
Abstract Number: 1826 • 2016 ACR/ARHP Annual Meeting
STAT3 Phosphorylation Mediates the Stimulatory Effects of Interferon Alpha on B Cell Differentiation and Activation in SLE
Julie Ducreux¹, Floor Aleva², Aurelie Degroof³, Alina Ferster⁴, Andre van der Ven², Frank van de Veerdonk², Frédéric A. Houssiau¹ and Bernard R. Lauwerys¹, ¹Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Department of General Internal Medicine, Radboud University, Nijmegen, Netherlands, ³Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ⁴Service d'Onco-Hématologie, Hôpital Reine Fabiola, Brussels, Belgium
Background/Purpose: In our previous work, we reported a link between interferon alpha inhibition and decreased expression of B cell activation genes in ex vivo whole…
Abstract Number: 1827 • 2016 ACR/ARHP Annual Meeting
Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types
Hao Liu¹, Brandon Higgs², William Rees³, Chris Morehouse⁴, Katie Streicher⁵, P Brohawn², G. Illei⁶ and K Ranade², ¹Translational Medicine, Medimmune, LLC, Gaithers, MD, ²MedImmune, Gaithersburg, MD, ³Translational Medicine, Medimmune, LLC, Gaithersburg, MD, ⁴Medimmune, LLC, Gaithers, MD, ⁵Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁶Medimmune, Gaithersburg, MD
Background/Purpose: Type I interferon (IFN) has been implicated in SLE pathogenesis, and the majority of subjects with SLE have elevated expression of type I IFN-inducible…
Abstract Number: 1828 • 2016 ACR/ARHP Annual Meeting
Metabolic Reprogramming in CD4+CD28-CXCR3intt-bethi cells and Its Relevance to Pathogenesis in Patients with SLE
Shigeru Iwata¹, Yuka Kanno², Kei Sakata^3,4, Maiko Hajime¹, Masataka Torigoe^1,5, Naoaki Ohkubo¹, Shingo Nakayamada⁶, John J O'Shea⁷ and Yoshiya Tanaka⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyshu, Japan, ⁵Department of Endocrinology, Metabolism, Rheumatology and Nephrology,, Faculty of Medicine, Oita University, Yufu, Oita, Japan, Yufu, Japan, ⁶First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: CD4+ T cells play a crucial role in pathological process of Systemic Lupus Erythematosus (SLE). Recently, importance of metabolic reprograming in immunocompetent cells was…
Abstract Number: 1829 • 2016 ACR/ARHP Annual Meeting
Hyper-Responsiveness to TLR-4 Stimulation in SLE: Association with High Levels of Serum IFN-Alpha and a Distinct Inflammatory Cytokine Profile
Uma Thanarajasingam¹, Mark A. Jensen², Jessica M. Dorschner³, Danielle Vsetecka³, Shreyasee Amin⁴, Ashima Makol⁴, Floranne C. Ernste⁵, Thomas Osborn⁴, Vaidehi Chowdhary⁴ and Timothy B. Niewold⁶, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁶Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: IFN-alpha is a pathogenic factor in SLE. High serum interferon activity (IFN-high) marks a subgroup of SLE patients strongly associated with double-stranded DNA (dsDNA) antibodies.…
Abstract Number: 1830 • 2016 ACR/ARHP Annual Meeting
The Role of Tripartite Motif-Containing 21 in Interferon Signature of Systemic Lupus Erythematosus
Reikou Kamiyama¹, Ryusuke Yoshimi¹, Yumiko Sugiyama¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Toshinori Tsukahara¹, Yukiko Asami¹, Yohei Kirino¹, Mitsuhiro Takeno², Atsuhisa Ueda¹, Keiko Ozato³ and Hideaki Nakajima¹, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Program in Genomics of Differentiation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD
Background/Purpose: Although the increased expression of type I interferon (IFN)-inducible genes, called “IFN signature”, has been suggested to have important roles in the pathogenesis of…
Abstract Number: 1831 • 2016 ACR/ARHP Annual Meeting
A Novel Graph Theoretic Approach Applied to Modular Repertoire Analysis Identifies a Dual Molecular Progression in Adult SLE Patients, with Distinct Interferon and Neutrophil Transcription Patterns
Ilya Korsunski¹, Noémie Jourde-Chiche^2,3, Peter K. Gregersen¹, Damien Chaussabel⁴, Laurent Chiche⁵ and Naomi I Maria⁶, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ³Nephrology, AP-HM, Department of Nephrology, CHU Conception, Marseille, France, ⁴Translational Medicine, Sidra Medical and Research Center, Doha, Qatar, ⁵internal medicine, Hopital Europeen, Marseille, France, ⁶Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Gene expression studies support a pivotal role for type I interferon (IFN) in SLE. Previous work using a modular repertoire analysis based on co-clustered…
Abstract Number: 1832 • 2016 ACR/ARHP Annual Meeting
Increased Interferon b Expression in Bone Marrow Mediates a Senescent Phenotype and Impaired Production of Immunomodulatory Factors By SLE Mesenchymal Stromal Cells
Lin Gao¹, Jennifer H. Anolik² and R. John Looney², ¹medicine- allergy, immunology and rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow mesenchymal stromal cells (MSCs) are multipotent stem cells that create a special microenvironment for hematopoiesis and immunity. MSCs display robust immunomodulatory properties…
Abstract Number: 1833 • 2016 ACR/ARHP Annual Meeting
Autoantibody Response to TROVE2 in Systemic LUPUS Erythematosus Patients
Elvira Vicens Bernabeu¹, Elena Grau Garcia¹, Augusto Juste², Isidro Monzo², Roberto Tejero², Sergi Morais³, Jose Luis Lopez Paz³, Rosa Puchades³, Angel Maquieira³, Jose Andres Roman Ivorra¹ and David Gimenez Romero³, ¹Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Physical-Chemistry Department, UV, Valencia, Spain, ³Department of Chemistry, IDM, UPV, Valencia, Spain
Background/Purpose: Ro60/TROVE2 is a clinically important member of the nuclear antigen family. It binds synergistically YRNAs, allowing the formation of a stable complex with exoribonuclease…
Abstract Number: 1834 • 2016 ACR/ARHP Annual Meeting
Commensal Ro60 Autoantigen Ortholog Cross-Reactivity in Human Lupus and Gnotobiotic Models
Teri Greiling¹, Carina Dehner², Stephen Renfroe³, Xinguo Chen⁴, Kevin Hughes⁴, Silvio M. Vieira³, William Ruff³, Marco Boccitto⁴, Andrew Goodman⁵, Sandra L. Wolin⁴ and Martin Kriegel^3,6, ¹Dermatology and Immunobiology, Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, new haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Cell Biology, Yale School of Medicine, New Haven, CT, ⁵Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁶Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: The earliest autoantibodies in lupus are directed against the autoantigen Ro60, an RNA binding protein with orthologs that we identified in a subset of…
Abstract Number: 1835 • 2016 ACR/ARHP Annual Meeting
Study on the Expression of NOD2 in Lupus Nephritis and Its Potential Signaling Pathway
Ou Jin, Chengcheng Hou, Qiuxia Li, Xi Zhang, Qiujing Wei, Hongyue Huang, Mingli Qiu and Jieruo Gu, Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China
Background/Purpose: () - -the Immunohistochemistry was to observe the expression of NOD2 in renal biopsies eal-time uantitative olymerase hain eactionPCR was used to detect the level of…
Abstract Number: 1836 • 2016 ACR/ARHP Annual Meeting
SLE Bone Marrow Contains Factors That Promote Type I Interferon Activation
Nida Meednu¹, Anna Bird², Jennifer Barnard², Mariana Kaplan³ and Jennifer H. Anolik², ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³NIAMS/NIH, Bethesda, MD
Background/Purpose: SLE is characterized by the inappropriate activation of type I Interferon (IFN) and increases in apoptosis and NETosis by neutrophils, which in combination with…
Abstract Number: 1837 • 2016 ACR/ARHP Annual Meeting
Genetic Susceptibility Loci for Systemic Lupus Erythematosus in the Dominican Republic Population
Esthela Loyo¹, Zheng Liu², Carmen Tineo³, Paola Gottschalk³, Glenny Paulino³, Yangsheng Yu², Yinshi Yue², Michelene Hearth-Holmes⁴, Zhixin Zhang⁵ and Kaihong Su², ¹Departamento de Reumatologia, Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago, Dominican Republic, ²Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, Hospital Regional Universitario José Ma Cabral Baez, Santiego, Dominican Republic, ⁴Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with marked disparities in prevalence and disease characteristics among different populations. Those disparities are believed…
Abstract Number: 1838 • 2016 ACR/ARHP Annual Meeting
Antibodies Against Bacterial Products Curli/DNA Are Found in Lupus Patients and Are Associated with Disease Flares
Ryan Pachucki¹, Sarah Tursi², Chelsea Corradetti¹, Lynne Kohler³, Stefania Gallucci², Cagla Tukel² and Roberto Caricchio¹, ¹Medicine Rheumatology, Lewis Katz School of Medicine, Philadelphia, PA, ²Microbiology and Immunology, Lewis Katz School of Medicine, Philadelphia, PA, ³Lewis Katz School of Medicine, Philadelphia, PA
Background/Purpose: Bacterial infections are a major contributor to morbidity and mortality in SLE, a known trigger of flares and they are often difficult to distinguish…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].